P705: Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programmeECCO'24Year: 2024
Authors: Lichtenstein, G.R.(1);Allegretti, J.R.(2);Loftus Jr, E.V.(3);Irving, P.M.(4);Banerjee, R.(5);Charabaty, A.(6);Kuehbacher, T.(7);Bananis, E.(8);Woolcott, J.C.(8);Dalam, A.B.(9);Lazin, K.(10);Keating, M.(11);McDonnell, A.(12);Danese, S.(13)*;
(1)Perelman School of Medicine at the University of Pennsylvania, Division of Gastroenterology, Philadelphia- PA, United States;(2)Brigham and Women’s Hospital, Division of Gastroenterology- Hepatology and Endoscopy, Boston- MA, United States;(3)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester- MN, United States;(4)Guy’s and St Thomas’ Hospital, IBD Unit, London, United Kingdom;(5)Asian Institute of Gastroenterology, Department of Gastroenterology, Hyderabad, India;(6)Johns Hopkins School of Medicine, Division of Gastroenterology and Hepatology, Washington DC, United States;(7)St Marien- and Annastift Hospital, Department of Internal Medicine/Gastroenterology, Ludwigshafen a. Rhein, Germany;(8)., Pfizer Inc, Collegeville- PA, United States;(9)., Pfizer Inc, Manila, Philippines;(10)., Pfizer AG, Zürich, Switzerland;(11)., Pfizer Inc, New York- NY, United States;(12)., Pfizer Ltd, Sandwich, United Kingdom;(13)IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Division of Gastroenterology and Endoscopy, Milan, Italy;
P706: Tofacitinib in Moderate to Severe Ulcerative Colitis patients naïve to biological therapy: A prospective real world analysis of efficacy and safetyECCO'24Year: 2024
Authors: Banerjee, R.(1)*;Dhanush, M.(1);Raghunathan, N.(1);Pal, P.(1);Joshi, V.(1);Patel, R.(1);Godbole, S.(1);Akki, Y.(1);Valluri, S.(1);Nagasuri, P.(1);Haridas, A.(1);
(1)AIG Hospitals, Inflammatory Bowel Disease, Hyderabad, India;
P707: Real-world Long-term efficacy of ustekinumab in the treatment of Perianal Fistulizing Crohn@E@s disease: Results from a single-center retrospective studyECCO'24Year: 2024
Authors: Chen, Q.(1)*;Gong, Y.(1);Yang, F.(2);Qiao, L.(1);Wang, H.(1);Zhang, D.(1);Wang, C.(1);Zhu, Z.(1);Yang, B.(1);
(1)Affiliated Hospital of Nanjing University of Chinese Medicine- Jiangsu Province Hospital of Chinese Medicine, Department of Colorectal Surgery, Nanjing, China;(2)University of New South Wales, School of mathematics and statistics, Sydney, Australia;
P708: Multiple Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes in Inflammatory Bowel Disease: A Real-World Effectiveness Analysis in a National U.S. CohortECCO'24Year: 2024
Authors: Hou, J.K.(1,2)*;Pham, C.(1);Xu, A.(1);Sansgiry, S.(1);Modi, V.(1);Waljee, A.(3,4);
(1)Baylor College of Medicine, Medicine, Houston, United States;(2)Michael E. DeBakey VA Medical Center, Medicine, Houston, United States;(3)University of Michigan, Medicine, Ann Arbor, United States;(4)Ann Arbor VA Healthcare System, Medicine, Ann Arbor, United States;
P709: Role of NOD2 single nucleotide polymorphisms on ustekinumab drug durability in adult patients with Crohn’s diseaseECCO'24Year: 2024
Authors: Elleisy, N.(1)*;Behnisch, S.(1);Huth, A.(1);Schäffler, H.(1);Jaster, R.(1);Lamprecht, G.(1);Reiner, J.(1);
(1)University Hospital Rostock, Department of Gastroenterology, Rostock, Germany;
P710: Prevalence, Characteristics and Management of Patients with Difficult-To-Treat Inflammatory Bowel Disease: A Cross-Sectional Study From a Tertiary Referral CenterECCO'24Year: 2024
Authors: ParigiMD, T.L.(1)*;Massimino, L.(1);Carini, A.(1);Allocca, M.(1);D@E@Amico, F.(1);Furfaro, F.(1);Zilli, A.(1);Peyrin-Biroulet, L.(2);Ungaro, F.(1);Danese, S.(1);
(1)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(2)University of Lorraine, Inserm- NGERE- F-54000, Nancy, France;
P711: Outcomes of Outpatient Biologic Exposed Patients Hospitalized with Severe Ulcerative ColitisECCO'24Year: 2024
Authors: Al-Bawardy, B.(1)*;Al Sulais, E.(2);Mukhtar, M.(3);Hart, A.(3);Raine, T.(4);
(1)King Faisal Specialist Hospital and Research Ceneter, Department of Internal Medicine- Division of Gastroenterology and Hepatology, Riyadh, Saudi Arabia;(2)King Fahad Specialist Hospital, Department of Medicine, Dammam, Saudi Arabia;(3)St. Mark’s Hospital, Department of Gastroenterology, London, United Kingdom;(4)Addenbrooke’s Hospital- University of Cambridge, Department of Gastroenterology, Cambridge, United Kingdom;
P712: Effectiveness of switching from intravenous to subcutaneous infliximab in Inflammatory Bowel Disease patients: A combined analysis of real-world evidenceECCO'24Year: 2024
Authors: Cummings, F.(1)*;Buisson, A.(2);Smith, P.J.(3);Rahmany, S.(4);Subramanian, S.(5);Kwon, B.(6);Park, S.(6);Lee, Y.N.(6);Fumery, M.(7);
(1)Southampton General Hospital, Gastroenterology, Southampton, United Kingdom;(2)Clermont Auvergne University, IBD Unit, Clermont-Ferrand, France;(3)Royal Liverpool Hospital, Gastroenterology, Liverpool, United Kingdom;(4)University Hospital Southampton NHS Foundation Trust, Gastroenterology, Southampton, United Kingdom;(5)Cambridge University Hospital NHS Trust, Gastroenterology, Cambridge, United Kingdom;(6)Celltrion Healthcare, Medical Department, Incheon, Korea- Republic Of;(7)CHU Amiens Picardie, Hepatogastroenterology, Amiens, France;
P713: The introduction of an intestinal ultrasound service significantly reduces diagnostic endoscopy usage in an Inflammatory Bowel Disease service – The SCOPELESS StudyECCO'24Year: 2024
Authors: Feng, G.(1)*;Little, R.(1);Ardalan, Z.(1);Friedman, A.(1);Smith, R.(1);Taylor, K.(1);Sparrow, M.(1);
(1)Alfred Health, Gastroenterology, Melbourne, Australia;
P714: Immunogenicity and safety of adjuvated recombinant zoster vaccine in IBD patients on different immunosuppressive therapies.ECCO'24Year: 2024
Authors: Franco, M.(1)*;De Bona, M.(2);Brun, P.(3);Bortoluzzi, M.(3);Nappo, A.(4);Zaetta, D.(2);Roncen, E.(2);Riguccio, G.(2);Boito, C.(5);Piselli, P.(6);Castagliuolo, I.(3);Savarino, E.V.(7);BudaPhD, A.(8);
(1)Gastroenterology, Gastrointestinal Oncological Surgery, Feltre, Italy;(2)AULSS1 Dolomiti- Gastrointestinal Inflammatory Departimental Unit- S. Maria del Prato Hospital, Gastrointestinal Oncological Surgery, Feltre, Italy;(3)University of Padova, Molecular Medicine, Padova, Italy;(4)INMI- IRCCS L. Spallanzani, Epidemiology and Preclinical Research, Roma, Italy;(5)Aulss1 Dolomiti- Laboratory Medicine- Santa Maria del Prato Hospital, Pathology and Laboratory Medicine, Feltre, Italy;(6)INMI L. Spallanzani- IRCCS, Epidemiology and Preclinical Research, Roma, Italy;(7)University of Padova, Oncological Gastrointestinal Surgical Sciences, Padova, Italy;(8)AULSS1 Dolomiti- Gastroenterology- S. Maria del Prato Hospital, Gastrointestinal Oncological Surgery, Feltre, Italy;
P715: Multiparametric assessment of IBD and SpA-IBD patients to explore disease biomarkers and response predictorsECCO'24Year: 2024
Authors: Privitera, G.(1)*;Parisio, L.(2);Perniola, S.(3);Varca, S.(4);Alivernini, S.(5);Tolusso, B.(6);Petito, V.(4);Napolitano, D.(2);Schiavoni, E.(2);Scaldaferri, F.(2);Gasbarrini, A.(4);Armuzzi, A.(7);Gremese, E.(4);Guidi, L.(2);Pugliese, D.(2);
(1)Università degli studi di Milano, Dipartimento di scienze della salute, Milan, Italy;(2)Fondazione Policlinico A.Gemelli IRCCS, UOC CEMAD IBD Unit, Rome, Italy;(3)Fondazione Policlinico A.Gemelli IRCCS, UOSD di Immunologia Clinica, Rome, Italy;(4)Fondazione Policlinico A.Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy;(5)Fondazione Policlinico A.Gemelli IRCCS, UOC di Reumatologia, Rome, Italy;(6)Fondazione Policlinico A.Gemelli IRCCS, Immunology Research Core Facility, Rome, Italy;(7)Humanitas Clinical and Research Center IRCCS, Gastroenterologia, Milan, Italy;
P716: Efficacy and safety of upadacitinib during induction in Crohn’s disease: Real-world experienceECCO'24Year: 2024
Authors: Jairath, R.(1)*;Zoughlami, A.(2);Pilote, N.(3);Afif, W.(1);Bitton, A.(1);Wild, G.(1);Narula, N.(4);Lakatos, P.L.(1);Bessissow, T.(1);
(1)McGill University Health Centre, Department of Gastroenterology, Montreal, Canada;(2)McGill University Health Centre, Department of Internal Medicine, Montreal, Canada;(3)McGill University Health Centre, McGill University - Faculty of Medicine, Montreal, Canada;(4)McMaster University - Hamilton Health Sciences, Department of Gastroenterology, Hamilton, Canada;
P717: Evaluating the performance of Large Language Models in responding to patients@E@ health queries: A comparative analysis with medical experts.ECCO'24Year: 2024
Authors: Yan, Z.(1)*;Lu, S.(2);Xu, D.(2);Yang, Y.(3);Wang, H.(4);Mao, J.(5);Fan, Y.(6);Chen, Y.(2);Tseng, H.C.(7);
(1)The First Affiliated Hospital of Zhejiang Chinese Medical University, Department of Gastroenterology, Hangzhou, China;(2)The Second Affiliated Hospital- Zhejiang University School of Medicine, Center for Inflammatory Bowel Diseases- Department of Gastroenterology, Hangzhou, China;(3)Zhejiang University School of Medicine, Clinical Medical College, Hangzhou, China;(4)The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Department of Gastroenterology, Huai’an, China;(5)Zhejiang Chinese Medical University, The Second Clinical Medical College, Hangzhou, China;(6)The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Key Laboratory of Gastrointestinal Diseases Pathophysiology-Department of Gastroenterology, Hangzhou, China;(7)National Taiwan University of Science and Technology, Graduate Institute of Digital Learning and Education, Taipei, Taiwan;
P719: Vitamin and micronutrient excess in patients with Crohn’s disease under oral ambulatory exclusive enteral nutritionECCO'24Year: 2024
Authors: Oliveira, R.(1)*;Mendes, B.(2);Cunha Neves, J.(1);Amorim, E.(2);Roseira, J.(1);Tavares de Sousa, H.(1);
(1)Algarve University Hospital Centre, Gastroenterology Department, Portimão, Portugal;(2)Algarve University Hospital Centre, Colorectal Unit - General Surgery Department, Portimão, Portugal;
P720: Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn diseaseECCO'24Year: 2024
Authors: H. Gibble, T.(1);Macey, J.(2);Makin, H.(2);Rosu, R.(3);Mellor, K.(2);Kitchen, H.(2);Carlier, H.(4);Dubinsky, M.C.(5)*;
(1)Eli Lilly and Company, Value- Evidence- and Outcomes, Indianapolis, United States;(2)Clarivate, Clinical Outcomes Assessment, London, United Kingdom;(3)Eli Lilly and Company, Clinical Development, Indianapolis, United States;(4)Eli L, Medical, Indianapolis, United States;(5)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York City, United States;
P721: Dutch Crohn’s disease patients’ (pediatric and adult) perspectives of CDED diet and Modulife programECCO'24Year: 2024
Authors: Wijers, F.(1)*;van Zundert, S.(1);Verburgt, C.(2);van der Kruk, N.(2);van Limbergen, J.(2);Wierdsma, N.(1);
(1)Amsterdam University Medical Centers, Department of Nutrition and Dietetics, Amsterdam, The Netherlands;(2)Amsterdam University Medical Centers- Emma Children’s Hospital, Department of Pediatric Gastroenterology, Amsterdam, The Netherlands;
P722: The steep ramp test is a valid practical test to assess cardiorespiratory fitness in patients with inflammatory bowel diseaseECCO'24Year: 2024
Authors: Demers, K.(1,2,3,4)*;Bongers, B.C.(3,5);Jonkers, D.M.A.E.(2);Pierik, M.J.(2,4);Stassen, L.P.S.(1,3);
(1)Maastricht University Medical Center+, Department of Surgery, Maastricht, The Netherlands;(2)Maastricht University, Department of Gastroenterology-Hepatology- Research Institute for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(3)Maastricht University, Department of Surgery- Research Institute for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(4)Maastricht University Medical Center+, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands;(5)Maastricht University, Department of Nutrition and Movement Sciences- Research Institute for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;
P723: Upadacitinib in Crohn’s disease: Real world experience from an early access program in GreeceECCO'24Year: 2024
Authors: Papathanasiou, E.(1)*;Leonidakis, G.(1);Michalopoulos, G.(2);Manolakopoulos, S.(3);Siakavellas, S.(3);Theodoropoulou, A.(4);Tasovasili, A.(5);Giouleme, O.(6);Tzouvala, M.(7);Tsironi, E.(8);Viazis, N.(9);Michopoulos, S.(1);Zampeli, E.(1);
(1)General Hospital of Athens @D@Alexandra@D@, Department of Gastroenterology, Athens, Greece;(2)General Hospital of Athens @D@G. Gennimatas@D@, Department of Gastroenterology, Athens, Greece;(3)Hippocration General Hospital of Athens- University of Athens Medical School, Hepatogastroenterology Unit- 2nd Academic Department of Internal Medicine, Athens, Greece;(4)Venizeleio General Hospital, Department of Gastroenterology, Heraklion, Greece;(5)Academic Department of Internal Medicine- Hepatogastroenterology Unit- @D@Agioi Anargyroi@D@ General and Oncology Hospital of Kifisia- National and Kapodistrian University of Athens, Department of Gastroenterology, Athens, Greece;(6)Medical School- Aristotle University of Thessaloniki- Hippokration Hospital, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece;(7)General Hospital Nikaias-Piraeus @E@Agios Panteleimon@E@-General Hospital Dytikis Attikis @D@Agia Varvara@D@, Department of Gastroenterology, Athens, Greece;(8)Metaxa Memorial General Hospital, Department of Gastroenterology, Athens, Greece;(9)Evangelismos Hospital, Department of Gastroenterology, Athens, Greece;
